Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 12, 2023 08:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of Directors

NORCROSS, Ga., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today that Dr. Benjamin S....
October 03, 2023 08:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension Caused by Non-Alcoholic SteatoHepatitis Liver Cirrhosis

NORCROSS, Ga., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, today reported the positive outcome of its...
September 26, 2023 08:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023

NORCROSS, Ga., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, today announced it will participate in the...
September 13, 2023 17:22 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023

NORCROSS, Ga., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be...
September 11, 2023 08:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023

NORCROSS, Ga., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be...
September 07, 2023 12:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023

NORCROSS, Ga., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will...
August 14, 2023 08:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2023 and Provides Business Update

NORCROSS, Ga., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and...
May 15, 2023 08:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2023 and Provides Business Update

NORCROSS, Ga., May 15, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and...
April 27, 2023 08:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Investment Conference May 2, 2023

NORCROSS, Ga., April 27, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be...
April 18, 2023 08:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics’ Statement Following the Recent 2023 Emerging Topic Conference on NASH Cirrhosis, Sponsored by the American Association for the Study of Liver Diseases

NORCROSS, Ga., April 18, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, attended the 2023 Emerging Topic...